Zeltia €900 million reverse merger with PharmaMar

Overview:

• Zeltia has made a reverse merger with PharmaMar, a biopharmaceutical company focused on the research, development and commercialisation of innovative marine-derived anticancer drugs.
• The company has subsidiaries in Germany, Italy, France, Switzerland, United Kingdom and the United States, an important pipeline of drug candidates and a robust R&D oncology programme. 
• The transaction was a challenge in the highly regulated pharma sector as there was no interruption of Zeltia's listing during the reverse merger process.
• The reverse merger and listing of PharmaMar may lead to future transactions and a listing of PharmaMar on the Nasdaq stock market.

Adam Majeed - Regional editor